Esther Rajavelu sold $95k of SPRO
See Remarks at Spero Therapeutics, Inc.. 40,270 shares at an average of $2.37, traded Nov 7, 2025, filed Nov 12, 2025.
Score components
- +15RoleOfficer
- +10Trade size$95k at market
- 0Share of holdings soldSold 4.4% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-25-278370, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 7, 2025 | SOpen-market sale Common Stock | -40,270 | $2.37 | $95k | 869,450 | Nov 12, 2025 |
Related signals
Other insiders at Spero Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | Spero Therapeutics, Inc. | Timothy Keutzer Chief Operating Officer | $3,339 1,695 shares | -0% | |
| 23Weak | Spero Therapeutics, Inc. | Ankit Mahadevia director | $13k 6,572 shares | -1% | |
| 26Weak | SPROsell Spero Therapeutics, Inc. | Timothy Keutzer Chief Operating Officer | $44k 56,537 shares | -7% | |
| 29Weak | SPROsell Spero Therapeutics, Inc. | Esther Rajavelu CFO & CBO | $53k 40,596 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.